MENU
+Compare
PACB
Stock ticker: NASDAQ
AS OF
Jun 9, 04:59 PM (EDT)
Price
$1.21
Change
+$0.07 (+6.14%)
Capitalization
976.68M

PACB Pacific Biosciences of California Forecast, Technical & Fundamental Analysis

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems... Show more

Industry: #Biotechnology
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PACB with price predictions
May 28, 2025

PACB's RSI Oscillator ascends from oversold territory

The RSI Oscillator for PACB moved out of oversold territory on May 28, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In of the 27 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PACB advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

PACB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 14, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PACB as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PACB turned negative on May 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PACB entered a downward trend on May 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.393) is normal, around the industry mean (24.345). P/E Ratio (0.000) is within average values for comparable stocks, (79.080). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (4.610) is also within normal values, averaging (42.837).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

View a ticker or compare two or three
PACB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PACB is expected to report earnings to rise 16.93% to -17 cents per share on July 30

Pacific Biosciences of California PACB Stock Earnings Reports
Q2'25
Est.
$-0.18
Q1'25
Beat
by $0.04
Q4'24
Est.
$-0.20
Q3'24
Beat
by $0.05
Q2'24
Missed
by $0.41
The last earnings report on May 08 showed earnings per share of -15 cents, beating the estimate of -18 cents. With 11.23M shares outstanding, the current market capitalization sits at 976.68M.
A.I. Advisor
published General Information

General Information

a developer of sequencing system products to help scientists to resolve genetically complex problems

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1305 O’Brien Drive
Phone
+1 650 521-8000
Employees
796
Web
https://www.pacb.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

PACB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PACB has been loosely correlated with AZTA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then AZTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PACB
1D Price
Change %
PACB100%
+20.85%
AZTA - PACB
48%
Loosely correlated
-2.24%
ILMN - PACB
47%
Loosely correlated
+2.35%
LAB - PACB
46%
Loosely correlated
+5.83%
BRKR - PACB
43%
Loosely correlated
-0.48%
TWST - PACB
43%
Loosely correlated
-3.67%
More